"Using #genome information, Bay Area-based Personalis, Inc. created a blood test that detected evidence of #breastcancer tumors up to 15 months earlier than traditional imaging." Following findings shared at #ASCO24, Personalis's Dr. Richard Chen appeared on @NBCBayArea this week.

We celebrated our 5-year listing anniversary on NASDAQ! We’ve continuously been a leader in advanced genomics for cancer, and have strived to drive a new paradigm for cancer management, guiding care from biopsy through the life of the patient. #PrecisionOncology #Genomics #NGS

📣NEW WEBINAR ALERT: watch the recording highlighting NEW data presented at #ASCO24. One study found NeXT Personal® correctly identified all disease relapses with a 15 month lead time over imaging: bit.ly/4aUaRD7. #PrecisionOncology #ctDNA #Liquidbiopsy

"As technology costs decrease, expanding to broader early detection becomes more feasible," says CEO of Personalis, Chris Hall (Chris Hall) in a special report from Newsweek: bit.ly/4cUKZsd. #Cancer #PrecisionOncology

“We are excited to deepen our collaboration with Myriad by recognizing the importance of our respective patent estates in the field” - Chris Hall, CEO (@C_Hallbiotech). Learn more about our agreement with Myriad Genetics: bit.ly/4eSgYLz. #PrecisionOncology #MRD

ICYMI: Personalis' Dr. Richard Chen was featured talking about our ultra-sensitive test, NeXT Personal®, which can detect very small traces of cancer from a blood test from patients with cancer, and predict relapse months, even years ahead of imaging: bit.ly/4bOrkJE.

#WorldLungCancerDay. We stand united against #LungCancer by bringing ultra-precise MRD testing to patients with early-stage NSCLC. Learn about a study with 170+ patients, where we detected lung cancer recurrence, on median, about 6 months ahead of scans: bit.ly/40xPiVg

🎉 Let the countdown begin! 🎉 Just 30 days until BLOODPAC’s in-person third quarter meeting! Join us on September 4th and 5th in Fremont, California, hosted by Personalis, Inc.. We can't wait to see everyone there! 🚀 #BLOODPACQ3 #Countdown

We’re honored to be hosting BLOODPAC’s Q3 meeting this upcoming September at our Fremont headquarters! We look forward to a week of wonderful discussion and collaboration with fellow members. #LiquidBiopsy #PrecisionOncology

Empowering voices: our recent Women's Leadership Panel featured inspiring insights from Deepshikha Bhandari, Janet Lai, and Erin Ayash. Key takeaways: lead as a team captain, listen and show empathy, and have the courage to voice unique opinions. See more: bit.ly/4dHywIQ

📣Today we announced the expansion of our commercial relationship with Tempus. Following exceptionally strong demand of NeXT Personal®, we have agreed to accelerate efforts, expanding under several key terms… Read the full press release to learn more: bit.ly/3X558H0

Dr. Richard Chen highlights NeXT Personal®, an ultra-sensitive minimal residual disease (MRD) test, in article from Biocompare. NeXT Personal has been shown to detect early-stage lung and breast cancer recurrence months before cancer was seen on scans: bit.ly/3yJdivi.

ICYMI: Earlier, we announced expansion of our commercial relationship with Tempus. Following strong demand of our ultra-sensitive MRD product, both companies have agreed to accelerate efforts, including Tempus investing ~ $36 million into Personalis: bit.ly/3X8GqV4

🎉 Just 7 days to go! 🎉 BLOODPAC’s third quarter meeting is right around the corner! Join us in just one week on September 4th and 5th in Fremont, California, hosted by Personalis, Inc.. We’re so excited to see everyone there! 🚀 #BLOODPACQ3 #OneWeekOut

We’re excited to be at World CB & CDx next week in Boston! Visit us at booth # 25. Make sure to check out our presentation covering several impactful studies utilizing NeXT Personal® in early-stage #LungCancer and #BreastCancer. #PrecisionOncology #LiquidBiopsy #WorldCDx

We’re excited to be exhibiting at the 2024 Annual ESMO Congress in Barcelona, Spain! Stop by our booth 509 at #ESMO24 to learn more about our advanced solutions for oncology and make sure to check out our podium and poster presentations listed below. #PrecisionOncology

We’re excited to be hosting the BLOODPAC Q3 meeting next week! We look forward to seeing you there. #LiquidBiopsy #PrecisionOncology

We’re at World CB & CDx this week. Drop by booth # 25 and say hello! Check out our presentation on September 5th at 4:10PM EDT highlighting various impactful studies utilizing NeXT Personal® in early-stage lung and breast cancer. #PrecisionOncology #Biomarkers #CtDNA #WorldCDx

We're ready to welcome our members Personalis, Inc. for our Q3 meeting!

Our Executive Director Lauren Leiman kicking off Day 2 of our Q3 meeting at Personalis, Inc. !